The global stable angina management market is poised for significant growth, with its market value projected to surge from USD 11 Billion in 2023 to a staggering USD 25.1 Billion by 2033, according to recent market analysis. This robust growth trajectory reflects a Compound Annual Growth Rate (CAGR) of 8.6% over the forecast period of 2023 to 2033.
The market has been steadily expanding, as evidenced by a notable CAGR of 5.2% during the historical period of 2018 to 2022. This upward trend is driven by advancements in medical research, rising prevalence of stable angina, and an increasing demand for innovative treatment solutions to enhance patient outcomes.
Key Factors Driving Growth:
- Innovation in Treatment Modalities: Ongoing development of non-invasive and personalized therapies.
- Growing Patient Awareness: Increased emphasis on early diagnosis and management of stable angina.
- Healthcare Investments: Rising investments in cardiovascular healthcare and infrastructure worldwide.
As the global healthcare landscape evolves, the market for stable angina management is witnessing heightened interest from both established players and emerging innovators. The focus on improving patient care, combined with technological advancements, positions this market for sustained growth over the coming decade.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Stable Angina Management market grew at a CAGR of 5.2%.
- The global Stable Angina Management market is expected to grow with a 8.6% CAGR during 2023 to 2033.
- As of 2033, the Stable Angina Management Market is expected to reach USD 25.1 Billion.
- According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Stable Angina Management market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Stable Angina Management.” says an FMI analyst
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Market Competition:
Key players in the market include companies such as Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.
- In Early 2022, Health Canada granted approval for Corzyna as an additional therapy for patients suffering from stable angina who do not respond well to or cannot tolerate first-line therapies. Corzyna is considered a second-line therapy and is more expensive than the current treatment options for angina, with an annual cost of $2,555. This medication is recommended to be placed under Special Authorization for ClaimSecure groups subscribing to Managed Plans to ensure it is reserved for patients who have tried or are intolerant to more cost-effective options, while it will be fully covered for groups subscribing to Open Formularies.
Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.
Key Segments Profiled in the Stable Angina Management Industry Survey:
Drug Class:
- Beta Blockers
- Calcium Antagonists
- Anti-coagulants
- Antiplatelets
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
